FELIQS

FELIQS is a Japanese startup company funded with a total of $12 million to develop a portfolio of two patent-protected drug product candidates targeting two attractive multi-billion-dollar markets in ophthalmology and neonatology: Retinopathy of prematurity (ROP) – FLQ-101, a lipid peroxidation inhibitor repurposed to prevent ROP. FLQ-101 will be in Phase I/II dosing in the US in 2025. Age-related macular degeneration (AMD) – FLQ-105, proprietary lipid peroxidation and ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-105 will be in the phase 1 study in 2026. Each of these developmental candidates is identified through FELIQS’s proprietary screening platform targeting lipid peroxidation/ ferroptosis with proven efficacy from past prospective clinical trials.